

ChromaDex to Webcast Live at VirtualInvestorConferences.com on October 1, 2015

2015-09-28

Company Invites Institutional and Individual Investors to Attend Interactive Real-Time Virtual VirtualInvestorConferences.com

IRVINE, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today, that its Chief Executive Officer and Founder, Frank Jaksch will present live at VirtualInvestorConferences.com on October 1, 2015 at 1:45 PM Eastern Time.

DATE: Thursday, October 1, 2015

TIME: 1:45 PM Eastern Time

LINK: <http://tinyurl.com/101pre>

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

Recent Company Highlights

- **ChromaDex Launches New Patented Ingredient - IMMULINA(TM) - a Powerful, Natural Ingredient That Boosts the Immune System**
- **ChromaDex Announces Introduction of CVS Health NIAGEN(R) NR Age Defense Supplement**

- **ChromaDex Reports 5th Consecutive Quarter of Record Revenue as Q2 Ingredients Sales Climb 98%**
- **Results from First Human Clinical Study Demonstrate ChromaDex's NIAGEN(R) Nicotinamide Riboside Effectively Increases the Co-enzyme NAD+ and is Safe**

Learn more about the event: www.virtualinvestorconferences.com

About ChromaDex:

ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN[®] nicotinamide riboside; pTeroPure[®] pterostilbene; PUREENERGY[®], a caffeine-pTeroPure[®] co-crystal; ProC3G[®], a natural black rice containing cyanidin-3-glucoside; IMMULINA[™], a spirulina extract; and Suntava[®] Purple Corn derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 3, 2015, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

CONTACT: ChromaDex Company Contact:

Andrew Johnson, Director of Investor Relations

949-419-0288

andrewj@chromadex.com

ChromaDex Investor Contacts:

The Del Mar Consulting Group, Inc.

Robert B. Prag, President

858-794-9500

bprag@delmarconsulting.com

ChromaDex Corp